Table 4 Clinical characteristics of... | American Society of Hematology

Table 4

Clinical characteristics of cases and controls in a nested case-control study

Characteristic	Cases (n = 88)*	Controls (n = 218)*	P
Pre-HCT CV risk factors, n (%)
Smoking, ever	34 (38.6)	65 (29.8)	.14
Hypertension	18 (20.5)	19 (8.7)	< .01
Thyroid (hyper/hypo)	5 (5.7)	8 (3.7)	.43
Diabetes	3 (3.4)	5 (2.3)	.58
Dyslipidemia	3 (3.4)	7 (3.2)	.93
≥2 CV risk factors†	5 (5.7)	5 (2.3)	.13
Pre-HCT chemotherapy‡
Anthracycline, mg/m²
Mean (SD)	309.4 (105.5)	237.0 (102.0)	< .01
Cyclophosphamide, g/m²
Mean (SD)	5.2 (2.9)	5.0 (3.3)	.64
Ifosfamide, g/m²
Mean (SD)	10.0 (7.5)	16.0 (7.1)	.12
Procarbazine, g/m²
Mean (SD)	0.6 (1.7)	0.4 (1.5)	.70
Melphalan, g/m²
Mean (SD)	0.3 (0.5)	0.1 (0.7)	.33
Cisplatin, mg/m²
Mean (SD)	200.2 (69.0)	216.0 (102.8)	.40
Pre-HCT radiation, n (%)
Chest	15 (17.0)	22 (10.1)	.09
BMI at HCT, n (%)
≥30 kg/m²	19 (21.6)	47 (21.6)	.99
Post-HCT CV risk factors, n (%)
Hypertension	25 (28.4)	18 (8.3)	< .01
Diabetes	12 (13.6)	10 (4.6)	< .01
Thyroid (hyper/hypo)	8 (9.1)	21 (9.6)	.88
Dyslipidemia	12 (13.6)	25 (11.5)	.60
Post-HCT CV risk factors, n (%)
No comorbidity	48 (54.5)	161 (73.9)	< .01
1 CV risk factor	25 (28.4)	43 (19.7)
≥ 2 CV risk factors†	15 (17.0)	14 (6.4)

Characteristic	Cases (n = 88)*	Controls (n = 218)*	P
Pre-HCT CV risk factors, n (%)
Smoking, ever	34 (38.6)	65 (29.8)	.14
Hypertension	18 (20.5)	19 (8.7)	< .01
Thyroid (hyper/hypo)	5 (5.7)	8 (3.7)	.43
Diabetes	3 (3.4)	5 (2.3)	.58
Dyslipidemia	3 (3.4)	7 (3.2)	.93
≥2 CV risk factors†	5 (5.7)	5 (2.3)	.13
Pre-HCT chemotherapy‡
Anthracycline, mg/m²
Mean (SD)	309.4 (105.5)	237.0 (102.0)	< .01
Cyclophosphamide, g/m²
Mean (SD)	5.2 (2.9)	5.0 (3.3)	.64
Ifosfamide, g/m²
Mean (SD)	10.0 (7.5)	16.0 (7.1)	.12
Procarbazine, g/m²
Mean (SD)	0.6 (1.7)	0.4 (1.5)	.70
Melphalan, g/m²
Mean (SD)	0.3 (0.5)	0.1 (0.7)	.33
Cisplatin, mg/m²
Mean (SD)	200.2 (69.0)	216.0 (102.8)	.40
Pre-HCT radiation, n (%)
Chest	15 (17.0)	22 (10.1)	.09
BMI at HCT, n (%)
≥30 kg/m²	19 (21.6)	47 (21.6)	.99
Post-HCT CV risk factors, n (%)
Hypertension	25 (28.4)	18 (8.3)	< .01
Diabetes	12 (13.6)	10 (4.6)	< .01
Thyroid (hyper/hypo)	8 (9.1)	21 (9.6)	.88
Dyslipidemia	12 (13.6)	25 (11.5)	.60
Post-HCT CV risk factors, n (%)
No comorbidity	48 (54.5)	161 (73.9)	< .01
1 CV risk factor	25 (28.4)	43 (19.7)
≥ 2 CV risk factors†	15 (17.0)	14 (6.4)

Group-matching criteria included: age at HCT (±5 years), year of HCT (±2 years), and duration of follow-up.

Includes the following: hypertension, diabetes, thyroid disorder, or dyslipidemia.

Cumulative pre-HCT dose; analysis limited to survivors treated with therapeutic agent.